surpass cvot tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx Cardiovascular outcomes of semaglutide and

One freeze-thaw cycle can already change the medication

Our approach goes beyond managing symptomsfocusing on comprehensive, sustainable weight loss and wellness strategies customized to fit your unique lifestyle and goals

What Are the Differences in How Tirzepatide and Semaglutide Work

FDA's concerns with unapproved GLP-1 drugs used for weight loss

DOCTORS DRAW ATTENTION TO SAFETY ISSUES ASSOCIATED WITH POPULAR WEIGHT-LOSS DRUGS The FDA is reconsidering its decision to take the drug off the shortage list after pushback, but Eli Lilly confirmed to FOX Business on Tuesday that the shortage remains "resolved." On its website, the FDA said it confirmed with the "drugs manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand." However, federal officials noted that there still may be intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies